選單 研討會快訊 最新醫療快訊 藥物安全警訊 學會行事曆 Novel NSCLC Drug Wins FDA Designation FDA Grants RMAT Designation to HSV-Based Immunotherapy in NSCLC FDA Grants Orphan Drug Designation to Zenocutuzumab in Cholangiocarcinoma Videos What to Consider After Diagnosing a Patient With Ductal Carcinoma In Situ New Career Center Video: Learn how to balance clinical schedules with research, find mentorship, and take next steps in presenting your work with insights from Jonathan W. Lee, MD, MSc, and Chinmay Jani, MD. Trending 2026-02-12 查看更多 FDA Approves Pembrolizumab/Chemo in Platinum-Resistant GYN Indications BREAKING NEWS Data from the KEYNOTE-B96 trial support the FDA approval of the pembrolizumab regimen in these gynecologic malignancies. 2026-02-11 查看更多 RWO 1L lupatercept vs 2L ESA FACE-OFF: Low-Risk MDS ASH 2025 Explore real-world outcomes of Luspatercept and second-line ESAs in treating low-risk MDS, revealing promising response rates and treatment insights. Featured Video 2026-02-11 查看更多 Updates From the 2026 Tandem Meetings 2026 Tandem Meetings: What’s the Latest Research in Multiple Myeloma? Tandem Meetings Recap: T-Cell Efficacy and Safety Updates in Lymphoma New Career Center Video: Learn how to build and strengthen your oncology referral network with expert insights from Tarita Thomas, MD, PhD, MBA, FACRO. Watch Increasing Your Oncology Referral Network now. Videos Trending 2026-02-10 查看更多 Diagnostic Strategies in Sepsis Education Alert The Clock Is Ticking: Diagnostic Strategies for Timely Sepsis Intervention0.50 CME / CE / ABIM MOC How can you overcome diagnostic uncertainty with rapid tests and evidence-based strategies for timely sepsis care? 2026-02-10 查看更多 Using ESR1 Mutation Testing for Selecting Oral SERDs Education Alert Patients Progressing on an AI ± CDK4/6 Inhibitors: From Biomarkers to Treatment Strategies0.50 CME / CE / ABIM MOC Did you know that the prevalence of acquired ESR1 mutations increases after exposure to endocrine therapy? 2026-02-10 查看更多 Paving the Way With Oral Selective Estrogen Receptor Degraders Education Alert Endocrine Therapies in ER-Positive/HER2-Negative MBC: Understanding Their Benefits and Limitations to Optimize Treatment Selection0.50 CME / CE / ABIM MOC Did you know that approximately 50% of breast cancer patients who have been exposed to an AI over time in the metastatic setting develop an ESR1 mutation? 2026-02-09 查看更多 Advances in TRK Fusion-Positive Cancers Education AlertNavigating Advances in TRK Fusion-Positive Cancers: A Collaborative Journey From Testing to Therapy0.50 CME / ABIM MOC Are you regularly testing for TRK fusions in cancers with high fusion frequency? 2026-02-07 查看更多 123
